Clinical Applications of Circulating Tumor DNA in Response Evaluation and Relapse Monitoring of Primary Mediastinal Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.02.014
- Author:
Lu PAN
1
;
Xin-Miao JIANG
2
;
Yan TENG
1
;
Ning WANG
1
;
Ling HUANG
2
;
Han-Guo GUO
2
;
Si-Chu LIU
2
;
Xiao-Juan WEI
2
;
Fei-Li CHEN
2
;
Zhan-Li LIANG
2
;
Wen-Yu LI
1
Author Information
1. School of Medicine of South China University of Technology, Guangzhou 510006, Guangdong Province, China.
2. Department of Lymphoma, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, Guangdong Province, China.
- Publication Type:Journal Article
- Keywords:
primary mediastinal large B-cell lymphoma;
circulating tumor DNA;
PET/CT;
efficacy evaluation;
relapse monitoring
- MeSH:
Humans;
Circulating Tumor DNA/blood*;
Female;
Mediastinal Neoplasms;
Male;
Retrospective Studies;
High-Throughput Nucleotide Sequencing;
Prognosis;
Lymphoma, Large B-Cell, Diffuse/genetics*;
Middle Aged;
Adult;
Aged;
Neoplasm Recurrence, Local;
Mutation
- From:
Journal of Experimental Hematology
2025;33(2):407-415
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical significance of circulating tumor DNA (ctDNA) in response evaluation and relapse monitoring for patients with primary mediastinal large B-cell lymphoma (PMBCL).
METHODS:The clinical characteristics, efficacy and survival of 38 PMBCL patients in our hospital from January 2010 to April 2020 were retrospectively analyzed. The ctDNA monitoring was conducted by targeted next-generation sequencing (NGS).
RESULTS:Among the 38 patients, 26 cases were female, and 32 cases were diagnosed with Ann Arbor stage I-II. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate were 74.7% and 61.7%, respectively. Males and those with high aaIPI scores (3 points) had a relatively poor prognosis. The NGS results of 23 patients showed that STAT6 (65.2%), SOCS1 (56.5%), and TNFAIP3 (56.5%) were the most common mutated genes. Patients with stable disease (SD)/progressive disease (PD) exhibited enrichment in cell cycle, FoxO, and TNF signaling pathways. A total of 29 patients underwent end-of-treatment PET/CT (EOT PET/CT), and 16 of them received ctDNA monitoring with 12 negative. Among 6 patients with EOT PET/CT positive (Deauville 4), 4 underwent ctDNA monitoring, and 3 of them were negative, being still in continuous remission without any subsequent anti-tumor therapy.
CONCLUSION:CtDNA may be combined with PET/CT to assess efficacy, monitor relapse, and guide treatment of PMBCL.
